JOP20180103B1 - التركيب الصيدلاني للكاربيتوسين - Google Patents

التركيب الصيدلاني للكاربيتوسين

Info

Publication number
JOP20180103B1
JOP20180103B1 JOP/2018/0103A JOP20180103A JOP20180103B1 JO P20180103 B1 JOP20180103 B1 JO P20180103B1 JO P20180103 A JOP20180103 A JO P20180103A JO P20180103 B1 JOP20180103 B1 JO P20180103B1
Authority
JO
Jordan
Prior art keywords
carbetocin
pharmaceutical composition
relates
present
pharmaceutical compositions
Prior art date
Application number
JOP/2018/0103A
Other languages
English (en)
Inventor
Malm Mattias
Wisniewski Kazimierz
Nilsson Anders
Britta Siekmann Dr
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20180103(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of JOP20180103A1 publication Critical patent/JOP20180103A1/ar
Application granted granted Critical
Publication of JOP20180103B1 publication Critical patent/JOP20180103B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

يتعلق الإختراع الحالي بمركبات صيدلانية ذات إستقرارية مُحسنة.
JOP/2018/0103A 2010-09-30 2018-11-12 التركيب الصيدلاني للكاربيتوسين JOP20180103B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30

Publications (2)

Publication Number Publication Date
JOP20180103A1 JOP20180103A1 (ar) 2019-01-30
JOP20180103B1 true JOP20180103B1 (ar) 2022-03-14

Family

ID=43478408

Family Applications (3)

Application Number Title Priority Date Filing Date
JOP/2011/0297A JO3400B1 (ar) 2010-09-30 2011-09-28 مركب صيدلاني من كاربيتوسين
JOP/2018/0103A JOP20180103B1 (ar) 2010-09-30 2018-11-12 التركيب الصيدلاني للكاربيتوسين
JOP/2018/0102A JOP20180102B1 (ar) 2010-09-30 2018-11-12 مركب صيدلاني

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2011/0297A JO3400B1 (ar) 2010-09-30 2011-09-28 مركب صيدلاني من كاربيتوسين

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2018/0102A JOP20180102B1 (ar) 2010-09-30 2018-11-12 مركب صيدلاني

Country Status (26)

Country Link
US (4) US9566311B2 (ar)
EP (5) EP2621468B1 (ar)
JP (2) JP6038797B2 (ar)
KR (2) KR102102664B1 (ar)
CN (4) CN107080832B (ar)
AU (1) AU2011309762B2 (ar)
BR (2) BR122021001123B1 (ar)
CA (1) CA2812510A1 (ar)
CY (2) CY1119245T1 (ar)
DK (3) DK2621468T3 (ar)
ES (3) ES2637988T3 (ar)
HK (1) HK1246170A1 (ar)
HR (2) HRP20211969T1 (ar)
HU (3) HUE057187T2 (ar)
IL (3) IL225238B (ar)
JO (3) JO3400B1 (ar)
LT (2) LT3222272T (ar)
MX (1) MX352949B (ar)
NZ (1) NZ609719A (ar)
PL (3) PL3246018T3 (ar)
PT (3) PT2621468T (ar)
RS (2) RS62873B1 (ar)
RU (2) RU2737264C2 (ar)
SI (3) SI3246018T1 (ar)
TW (6) TWI532507B (ar)
WO (1) WO2012042371A2 (ar)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014013449A (es) * 2012-05-08 2014-12-08 Dilafor Ab Tratamiento de la hemorragia postparto (pph) con heparina modificada quimicamente o sulfato de heparan y un agente uterotonico.
CA2957224A1 (en) * 2014-09-19 2016-03-24 Ferring B.V. Method of treating prader-willi syndrome
HUE051974T2 (hu) 2014-10-01 2021-04-28 Oxytone Bioscience B V Szájban szétesõ, szülést szabályozó ágenst tartalmazó, szilárd halmazállapotú gyógyászati dózisegység
US10525099B2 (en) 2014-10-01 2020-01-07 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
CA2972975A1 (en) 2015-01-07 2016-07-14 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
AU2017250505B2 (en) 2016-04-12 2023-03-30 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的***给药的药用组合物及其制备方法
BR112020001832A2 (pt) * 2017-08-11 2020-07-28 Ferring B.V. método de produção de uma composição farmacêuti-ca
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
JP2021515005A (ja) 2018-03-01 2021-06-17 トライジェミナ， インコーポレイテッド 標識オキシトシンならびに製造および使用の方法
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
KR20210062648A (ko) 2018-09-20 2021-05-31 레보 테라퓨틱스 인코포레이티드 카르베토신 완제의약품 및 이를 제조하는 방법
EP3852723A4 (en) * 2018-09-20 2022-06-29 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
US20220080023A1 (en) * 2018-12-21 2022-03-17 Arecor Limited Novel composition
WO2020137880A1 (ja) * 2018-12-27 2020-07-02 国立大学法人北海道大学 オキシトシン誘導体及びその使用
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
AU2020380587A1 (en) 2019-11-04 2022-01-06 Ferring B.V. Intranasal administration of merotocin for improving lactation
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
TW202304498A (zh) 2021-03-26 2023-02-01 法商Ｏｔ４Ｂ公司 吞嚥困難之治療
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
EP1285667B1 (en) 1997-11-18 2006-06-14 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Pharmaceutical injectable solution of paracetamol and combinations of paracetamol with other active substances
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
JP2001233787A (ja) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
EP1556068B1 (en) 2002-10-03 2010-08-18 Neuropharmacology Services, LLC Oxytocin for use in the treatment of Autism and Asperger's disorder
EP1599222B1 (en) 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
AU2004218369A1 (en) 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101677948A (zh) * 2007-06-07 2010-03-24 纳斯泰克制药公司 卡贝缩宫素鼻用制剂和治疗孤独症的方法
DE602008003341D1 (de) 2007-07-02 2010-12-16 Sime Darby Malaysia Berhad Frittierfettzusammensetzung
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
CA2718148C (en) * 2008-03-31 2017-11-07 Ferring B.V. Oxytocin analogues
NZ592113A (en) * 2008-10-15 2012-04-27 Intarcia Therapeutics Inc Highly concentrated drug particles, formulations, suspensions and uses thereof

Also Published As

Publication number Publication date
KR101919119B1 (ko) 2018-11-15
HUE057187T2 (hu) 2022-04-28
US9566311B2 (en) 2017-02-14
EP3222272A1 (en) 2017-09-27
ES2905561T3 (es) 2022-04-11
TW202112389A (zh) 2021-04-01
TW201940188A (zh) 2019-10-16
TWI680773B (zh) 2020-01-01
DK3246018T3 (da) 2022-01-17
PL3222272T3 (pl) 2022-03-07
TWI661834B (zh) 2019-06-11
JO3400B1 (ar) 2019-10-20
DK3222272T3 (da) 2022-01-24
WO2012042371A3 (en) 2013-04-04
TWI650134B (zh) 2019-02-11
CA2812510A1 (en) 2012-04-05
CN107412728A (zh) 2017-12-01
SI3222272T1 (sl) 2022-01-31
RS62873B1 (sr) 2022-02-28
RU2604690C2 (ru) 2016-12-10
RU2016143751A (ru) 2018-12-18
ES2902418T3 (es) 2022-03-28
EP3222272B1 (en) 2021-11-03
MX2013003365A (es) 2013-07-29
EP3246018B1 (en) 2021-11-03
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
ES2637988T3 (es) 2017-10-18
EP3246018A1 (en) 2017-11-22
IL225238A0 (en) 2013-06-27
US20130210746A1 (en) 2013-08-15
PT2621468T (pt) 2017-09-08
SI3246018T1 (sl) 2022-02-28
RU2737264C2 (ru) 2020-11-26
AU2011309762A1 (en) 2013-04-04
TWI532507B (zh) 2016-05-11
EP4374878A2 (en) 2024-05-29
JOP20180102B1 (ar) 2022-03-14
PT3246018T (pt) 2022-01-13
HUE034367T2 (en) 2018-02-28
TWI750934B (zh) 2021-12-21
MX352949B (es) 2017-12-15
IL245326B (en) 2021-04-29
BR112013007362A2 (pt) 2016-07-12
TW201605465A (zh) 2016-02-16
HRP20171256T1 (hr) 2017-10-20
PL2621468T3 (pl) 2017-11-30
JOP20180103A1 (ar) 2019-01-30
KR20180123599A (ko) 2018-11-16
JOP20180102A1 (ar) 2019-01-30
KR102102664B1 (ko) 2020-04-22
IL245328B (en) 2022-04-01
CN107080832A (zh) 2017-08-22
BR122021001123B1 (pt) 2021-05-18
CY1124924T1 (el) 2023-01-05
LT2621468T (lt) 2017-11-27
BR112013007362B1 (pt) 2021-05-25
EP3936117A1 (en) 2022-01-12
WO2012042371A2 (en) 2012-04-05
KR20130136467A (ko) 2013-12-12
IL245326A0 (en) 2016-06-30
AU2011309762B2 (en) 2014-07-17
CN103124554A (zh) 2013-05-29
IL245328A0 (en) 2016-06-30
NZ609719A (en) 2014-07-25
US20170106044A1 (en) 2017-04-20
US20170106043A1 (en) 2017-04-20
SI2621468T1 (sl) 2017-10-30
HK1246170A1 (zh) 2018-09-07
DK2621468T3 (en) 2017-09-11
JP6250770B2 (ja) 2017-12-20
CN107080832B (zh) 2021-05-07
CY1119245T1 (el) 2018-02-14
PL3246018T3 (pl) 2022-05-02
IL225238B (en) 2018-07-31
TW201729797A (zh) 2017-09-01
EP2621468B1 (en) 2017-06-14
JP2017048226A (ja) 2017-03-09
US20230124105A1 (en) 2023-04-20
TW201605466A (zh) 2016-02-16
TWI746951B (zh) 2021-11-21
RS56220B1 (sr) 2017-11-30
CN104906032A (zh) 2015-09-16
RU2016143751A3 (ar) 2020-01-16
JP2013543492A (ja) 2013-12-05
RU2013112666A (ru) 2014-11-10
HUE056835T2 (hu) 2022-03-28
LT3222272T (lt) 2021-12-27
JP6038797B2 (ja) 2016-12-07
EP2621468A2 (en) 2013-08-07
HRP20211969T1 (hr) 2022-03-18

Similar Documents

Publication Publication Date Title
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
MX2013002264A (es) Composiciones pesticidas.
EA201590887A1 (ru) Композиция
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IN2015DN03029A (ar)
MX2013004981A (es) Composiciones y metodos para la administracion de agentes terapeuticos.
JO3154B1 (ar) عوامل مضادة لـ trpv4
MX2013000793A (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
JO3337B1 (ar) تركيبات صيدلية تشمل أليسبوريفير
EA201391643A1 (ru) Составы с замедленным высвобождением парацетамола
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
EP2568810A4 (en) COMPOSITIONS OF DARUNAVIR
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
MX2012008253A (es) Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.
IN2013MU03317A (ar)
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия
MX2015007959A (es) Polimorfo.
IN2012DN03290A (ar)
TN2010000225A1 (en) Injectable liquid paracetamol formulation
UA96060C2 (ru) Применение липофлавона как средства фригопротекторного действия